Osborne Clarke advised Oxford Biomedica on the acquisition of ABL Europe
Published on 22nd February 2024
Osborne Clarke advised London listed Oxford Biomedica plc on the French law aspects of its acquisition of 100% of the shares of ABL Europe SAS from Institut Mérieux.
Oxford Biomedica is a world-leading cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in the UK, the EU and the US.
ABL Europe is a European CDMO specialised in viral vector development and manufacturing, with facilities in Lyon and Strasbourg. Focused on delivering GMP-compliant viral vectors from early-stage to market, ABL Europe plays a pivotal role in the success of client-focused gene and immunotherapy solutions.
The Osborne Clarke teams for Oxford Biomedica:
Lead – M&A: Catherine Olive, partner – Julie Dahan, senior associate – Anthony Chung, associate.
Employment Law : Jérôme Scapoli, partner – Maud Parssegny and Alexandra Mestrallet, associates.
Commercial, Life Sciences: Thomas Devred, partner – Justine Pellerin, associate.
IP/ IT/ Data: Xavier Pican, partner – Alice Vigne, associate.
Real estate: François-Régis Fabre-Falret, partner – Julia Gaspard, counsel.
Tax: Dorothée Chambon, partner – Clément Petit, senior associate – Aminata Sarre, associate.
Compliance law: Lucie Mongin-Archambeaud, partner – Lucie Champetier, associate.
Client relationship: Matthew Edwards, partner UK.
Connect with one of our experts
